Exchange: NYSE·Updated 10:42 PM EDT
PFE logo

PFEPfizer Inc

$24.74
$0.13
(0.52%)
Today
Closed $25.08
$0.34
(1.36%)
Overnight
EarningsJul 29
Mkt Cap$143.68B
Vol41.12M
News
all
press releases
PFE Stock Reacts To Mixed Topline Results For Seagen-Origin Cancer Drug
In the overall population, sigvotatug vedotin did not demonstrate a statistically significant improvement in overall survival compared with chemotherapy medicine docetaxel.
Stocktwits
News Placeholder
More News
News Placeholder
Pfizer Announces Topline Phase 3 Results for Sigvotatug Vedotin in Previously Treated Metastatic Non-Squamous Non-Small Cell Lung Cancer
Pfizer Inc. (NYSE: PFE) today announced topline results from the Phase 3 SigVie-002 study (previously known as Be6A Lung-01) evaluating sigvotatug vedotin, an investigational, potential first-in-class integrin beta-6 (IB6) directed antibody-drug conjugate (ADC). The study enrolled adults with...
Business Wire
News Placeholder
AI, Biotech, And Healthcare Catalysts Drive Momentum
Several emerging public companies are attracting attention as artificial intelligence, healthcare innovation, medical technology, and international commercialization strategies continue converging across the market. From AI-powered drug discovery and regenerative medicine expansion to precision dermatology and medical device innovation, recent developments highlight how smaller companies are positioning themselves around some of the fastest-growing sectors in healthcare and technology. $TGNT, $NXTS, $AZTR, $ADTX, $TNON, $PFE
24-7 Market News
News Placeholder
Pfizer Stock Edges Lower Monday: What's Going On?
Pfizer shares are trading lower by about half a percent on Monday as investors digest a leadership transition in the finance seat.read more...
Benzinga
News Placeholder
Can Sanofi Rely on Dupixent to Drive Long-Term Revenue Growth?
SNY's Dupixent is expanding into new diseases and geographies, strengthening its position as a key driver of long-term revenue growth.
Zacks
News Placeholder
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
Amvuttra is the primary driver of ALNY's revenues, but growth from Givlaari, Oxlumo and Leqvio may help diversify the company's top line.
Zacks
News Placeholder
Pfizer Isn't Expecting to Make Any Big Acquisition in the Next Couple of Years, but It's Planning to Do This Instead
Key PointsPfizer has leaned on acquisitions in recent years to strengthen its growth prospects...
Nasdaq News: Markets
News Placeholder
Could Pfizer Stock Be Your Ticket to Generational Wealth?
Key PointsPfizer is one of the world's most respected pharmaceutical companies...
Nasdaq News: Markets
News Placeholder
Own 500 Shares of Pfizer and JNJ and Here's Your Annual Dividend Income
Own 500 Shares of Pfizer and JNJ and Here's Your Annual Dividend Income...
Yahoo! Finance: News
News Placeholder
Pfizer's Dividend Yield is 10X Bigger Than Eli Lilly's. Does That Make It the Better Stock for Income Investors?
Key PointsEli Lilly is a market darling because it is a leader in the GLP-1 weight-loss market...
Nasdaq News: Markets
<
1
2
...
>

Advertisement|Remove ads.